TLR9 (Toll-like receptor 9) variants and mutations
TLR9 (also known as Toll-like receptor 9) is a human protein-coding gene encoding a toll-like receptor 9 protein. It detects unmethylated CpG-rich DNA in endosomes and activates innate immune and type I interferon responses. Dysregulated signaling can contribute to autoimmunity, while agonists and antagonists of the pathway are being developed for cancer and inflammatory disease. This analysis covers 1,506 TLR9 variants and mutations. Of these, 97% have computational variant effect predictions. Disease context includes rheumatoid arthritis, malaria, and systemic lupus erythematosus. Example TLR9 variants include G2D, F3L, and R5C.
Variant analysis overview
- Gene: TLR9
- Protein: Toll-like receptor 9
- UniProt accession: Q9NR96
- Organism: Homo sapiens
- Variants analyzed: 1506
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 1,001 unspecified-consequence records; 2 stop lost; 1 stop retained variant; 206 synonymous variants; 244 missense variants; 29 frameshift variants; 6 in-frame deletions; 13 stop-gained variants; 1 protein altering variant; 1 in-frame insertions; 2 substitution
- Prediction scores: 1,467 variants have prediction scores (97% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: rheumatoid arthritis, malaria, systemic lupus erythematosus, COVID-19, cutaneous lupus erythematosus, non-small cell lung carcinoma, colorectal cancer, pneumonia, melanoma, Sjogren syndrome, breast cancer, pulmonary sarcoidosis.
Protein structure and variant hotspots
- Protein features: 1 transmembrane segments; 1 domains; 6 binding sites; 15 post-translational modification sites.
- Structural context: 419 variants have structural context.
- PTM context: 25 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable TLR9 variants
Examples include G2D, F3L, R5C, R5H, S6R, A7D, A7P, A7T. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- G2D (p.Gly2Asp), gnomAD rs1240996318, REVEL 0.03, CADD 12.70
- F3L (p.Phe3Leu), gnomAD rs1273048547, REVEL 0.07, CADD 7.18
- R5C (p.Arg5Cys), rs5743842, ClinGen CA2430897, ClinVar RCV000971495, UniProt VAR 024668, REVEL 0.14, CADD 0.05, Benign, not provided
- R5H (p.Arg5His), rs199759037, ClinGen CA2430896, NCI-TCGA Cosmic COSV5972, ClinVar RCV004229038, REVEL 0.06, CADD 0.23, Uncertain significance, not specified
- S6R (p.Ser6Arg), 1000Genomes rs56172276, ExAC rs56172276, TOPMed rs56172276, gnomAD rs56172276, REVEL 0.13, CADD 0.00
- A7D (p.Ala7Asp), gnomAD rs1362089750, REVEL 0.08, CADD 11.20
- A7P (p.Ala7Pro), ESP rs150459369, ExAC rs150459369, TOPMed rs150459369, gnomAD rs150459369
- A7T (p.Ala7Thr), rs150459369, ESP rs150459369, ExAC rs150459369, TOPMed rs150459369, REVEL 0.05, CADD 0.33, Variant assessed as somatic; moderate impact.
- H9Y (p.His9Tyr), TOPMed rs202195635, gnomAD rs202195635, REVEL 0.04, CADD 5.81, Uncertain significance, not specified
- P10L (p.Pro10Leu), ESP rs370157255, ExAC rs370157255, TOPMed rs370157255, gnomAD rs370157255, REVEL 0.34, CADD 22.00
- L11M (p.Leu11Met), gnomAD rs1270141629, REVEL 0.23, CADD 19.40
- S12C (p.Ser12Cys), NCI-TCGA Cosmic COSV1005, Variant assessed as somatic; moderate impact.
- S12P (p.Ser12Pro), TOPMed rs1699598705, REVEL 0.15, CADD 20.50
- L13F (p.Leu13Phe), gnomAD rs1288470860, REVEL 0.10, CADD 20.50
- V15M (p.Val15Met), TOPMed rs1394861605, gnomAD rs1394861605, REVEL 0.13, CADD 22.90
- Q16K (p.Gln16Lys), Ensembl rs1577981421
- I18M (p.Ile18Met), rs139242193, ClinGen CA2430888, ClinVar RCV004264304, ESP rs139242193, REVEL 0.05, CADD 0.00, Likely benign, not specified
- I18V (p.Ile18Val), TOPMed rs1186360916, gnomAD rs1186360916, REVEL 0.03, CADD 0.09
- M19I (p.Met19Ile), ExAC rs746563907, TOPMed rs746563907, gnomAD rs746563907, REVEL 0.07, CADD 0.00
- M19T (p.Met19Thr), Ensembl rs1699598277, REVEL 0.09, CADD 0.01
- M19V (p.Met19Val), Ensembl rs2107296142, REVEL 0.08, CADD 0.02
- A21G (p.Ala21Gly), Ensembl rs2107296139, SIFT 0.05
- M22I (p.Met22Ile), TOPMed rs1241708543, gnomAD rs1241708543, REVEL 0.05, CADD 5.70
- T23A (p.Thr23Ala), TOPMed rs1312227021, gnomAD rs1312227021, REVEL 0.09, CADD 0.83
- T23I (p.Thr23Ile), gnomAD rs1277429812
- T23P (p.Thr23Pro), TOPMed rs1312227021, gnomAD rs1312227021
- A25V (p.Ala25Val), Ensembl rs918728499, SIFT 0.13
- L26P (p.Leu26Pro), ExAC rs754311214, gnomAD rs754311214, REVEL 0.13, CADD 18.10
- G27D (p.Gly27Asp), gnomAD rs1356994585, REVEL 0.37, CADD 23.90
- T28I (p.Thr28Ile), Ensembl rs866728864, SIFT 0.07
- L29F (p.Leu29Phe), TOPMed rs1245349119, gnomAD rs1245349119, REVEL 0.08, CADD 15.00
- L29S (p.Leu29Ser), NCI-TCGA Cosmic COSV1005, Variant assessed as somatic; moderate impact.
- A31D (p.Ala31Asp), TOPMed rs1354121442, gnomAD rs1354121442, REVEL 0.13, CADD 15.10
- A31V (p.Ala31Val), TOPMed rs1354121442, gnomAD rs1354121442, REVEL 0.06, CADD 16.00
- F32L (p.Phe32Leu), ESP rs367677799, ExAC rs367677799, TOPMed rs367677799, gnomAD rs367677799, REVEL 0.33, CADD 23.70
- C35F (p.Cys35Phe), Ensembl rs974271351
- C35R (p.Cys35Arg), TOPMed rs1239041600
- Q38L (p.Gln38Leu), Ensembl rs892160452, SIFT 0.16
- P39A (p.Pro39Ala), ExAC rs750628960, gnomAD rs750628960, REVEL 0.05, CADD 0.95
- H40Y (p.His40Tyr), gnomAD rs1229630759, REVEL 0.06, CADD 3.86
- G41S (p.Gly41Ser), ExAC rs200055519, TOPMed rs200055519, gnomAD rs200055519, REVEL 0.19, CADD 7.63
- N44K (p.Asn44Lys), gnomAD rs952850329, SIFT 1.00
- C45Y (p.Cys45Tyr), gnomAD rs201958063, REVEL 0.51, CADD 24.40
- W47* (p.Trp47Ter), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- F49V (p.Phe49Val), Ensembl rs180715569, SIFT 0.65
- S52F (p.Ser52Phe), ExAC rs775461893, gnomAD rs775461893, SIFT 0.00
- P54H (p.Pro54His), gnomAD rs1257387558, REVEL 0.48, CADD 25.40
- H55L (p.His55Leu), ExAC rs764964193, gnomAD rs764964193, REVEL 0.10, CADD 0.08
- H55N (p.His55Asn), rs2470998280, ClinGen CA353104298, ClinVar RCV004174165, Uncertain significance, not specified
- M58R (p.Met58Arg), ExAC rs55979550, gnomAD rs55979550, REVEL 0.15, CADD 1.42
- M58T (p.Met58Thr), ExAC rs55979550, gnomAD rs55979550, REVEL 0.08, CADD 0.44
- M58V (p.Met58Val), rs750403100, NCI-TCGA Cosmic COSV5972, TOPMed rs750403100, gnomAD rs750403100, REVEL 0.06, CADD 4.69, Variant assessed as somatic; moderate impact.
- A60T (p.Ala60Thr), ESP rs374677585, ExAC rs374677585, gnomAD rs374677585, REVEL 0.06, CADD 11.00
- P61S (p.Pro61Ser), ExAC rs770637836, TOPMed rs770637836, gnomAD rs770637836, REVEL 0.09, CADD 13.80
- P61T (p.Pro61Thr), ExAC rs770637836, TOPMed rs770637836, gnomAD rs770637836
- R62C (p.Arg62Cys), ExAC rs200596305, TOPMed rs200596305, gnomAD rs200596305, REVEL 0.09, CADD 18.00
- R62H (p.Arg62His), TOPMed rs997645449, gnomAD rs997645449, REVEL 0.04, CADD 15.00
- G63D (p.Gly63Asp), ExAC rs772719609, gnomAD rs772719609, REVEL 0.16, CADD 0.28
- N64D (p.Asn64Asp), gnomAD rs1464508419, REVEL 0.19, CADD 23.50
- V65I (p.Val65Ile), gnomAD rs1171569842
- T66I (p.Thr66Ile), 1000Genomes rs189941642, TOPMed rs189941642, REVEL 0.26, CADD 22.90
- T66P (p.Thr66Pro), Ensembl rs1577981311
- S67R (p.Ser67Arg), ExAC rs780558008, gnomAD rs780558008, REVEL 0.13, CADD 18.90
- L68I (p.Leu68Ile), TOPMed rs1699596481, REVEL 0.49, CADD 23.50
- S69F (p.Ser69Phe), rs1183785127, NCI-TCGA Cosmic COSV1005, gnomAD rs1183785127, REVEL 0.23, CADD 18.70, Variant assessed as somatic; moderate impact.
- S69Y (p.Ser69Tyr), NCI-TCGA Cosmic COSV1005, REVEL 0.27, CADD 17.70, Variant assessed as somatic; moderate impact.
- L70* (p.Leu70Ter), ExAC rs756551977, gnomAD rs756551977, CADD 35.00
- L70S (p.Leu70Ser), ExAC rs756551977, gnomAD rs756551977, REVEL 0.53, CADD 24.90
- N73I (p.Asn73Ile), Ensembl rs1699596326, REVEL 0.53, CADD 25.70
- R74C (p.Arg74Cys), ExAC rs746281362, TOPMed rs746281362, gnomAD rs746281362, REVEL 0.31, CADD 27.90, Uncertain significance, not specified
- R74G (p.Arg74Gly), ExAC rs746281362, TOPMed rs746281362, gnomAD rs746281362
- R74H (p.Arg74His), rs781684117, ClinGen CA2430860, ClinVar RCV004472457, ExAC rs781684117, REVEL 0.08, CADD 18.90, Uncertain significance, not specified
- H77Q (p.His77Gln), gnomAD rs1319660926, REVEL 0.16, CADD 22.60
- H79Q (p.His79Gln), rs5743843, UniProt VAR 052364, ExAC rs5743843, TOPMed rs5743843, REVEL 0.03, CADD 2.43
- H79Y (p.His79Tyr), gnomAD rs1246235772, REVEL 0.10, CADD 15.20
- D82A (p.Asp82Ala), Ensembl rs1699595892, REVEL 0.17, CADD 23.50
- F83L (p.Phe83Leu), Ensembl rs1020495230, SIFT 0.00
- F83S (p.Phe83Ser), ExAC rs751767849, gnomAD rs751767849, REVEL 0.65, CADD 26.30
- A84V (p.Ala84Val), TOPMed rs1226463372, gnomAD rs1226463372, REVEL 0.07, CADD 8.36
- H85N (p.His85Asn), NCI-TCGA Cosmic COSV5972, SIFT 0.28, Variant assessed as somatic; moderate impact.
- H85P (p.His85Pro), gnomAD rs1299201604, REVEL 0.17, CADD 16.90
- H85Y (p.His85Tyr), rs201646083, ClinGen CA2430855, ClinVar RCV004472459, ExAC rs201646083, REVEL 0.09, CADD 8.98, Uncertain significance, not specified
- S88R (p.Ser88Arg), ExAC rs776469312, gnomAD rs776469312, REVEL 0.09, CADD 8.06
- R90Q (p.Arg90Gln), ExAC rs766103514, TOPMed rs766103514, gnomAD rs766103514, REVEL 0.12, CADD 15.60
- R90W (p.Arg90Trp), gnomAD rs1441565360, REVEL 0.27, CADD 23.90
- H91R (p.His91Arg), rs201572271, ClinGen CA2430849, ClinVar RCV004170585, ESP rs201572271, REVEL 0.16, CADD 0.00, Likely benign, not specified
- H91Y (p.His91Tyr), Ensembl rs1577981247, REVEL 0.12, CADD 0.84
- N93S (p.Asn93Ser), rs200206317, ClinGen CA2430848, ClinVar RCV004341498, ExAC rs200206317, REVEL 0.06, CADD 13.90, Uncertain significance, not specified
- L94F (p.Leu94Phe), gnomAD rs1699594948, REVEL 0.56, CADD 24.80
- L94R (p.Leu94Arg), gnomAD rs1166311703, REVEL 0.77, CADD 26.50
- W96* (p.Trp96Ter), ExAC rs747740029, TOPMed rs747740029, gnomAD rs747740029, CADD 36.00
- C98Y (p.Cys98Tyr), rs773699082, NCI-TCGA Cosmic COSV1005, ExAC rs773699082, gnomAD rs773699082, REVEL 0.38, CADD 24.60, Variant assessed as somatic; moderate impact.
- P99L (p.Pro99Leu), 1000Genomes rs5743844, ESP rs5743844, ExAC rs5743844, TOPMed rs5743844, REVEL 0.17, CADD 22.60
- P100L (p.Pro100Leu), ExAC rs781694864, TOPMed rs781694864, gnomAD rs781694864, REVEL 0.31, CADD 24.40
- P100A (p.Pro100Ala), rs781694864, []
- V101A (p.Val101Ala), gnomAD rs1389105161, REVEL 0.11, CADD 0.06
- G102D (p.Gly102Asp), Ensembl rs1699594546, REVEL 0.15, CADD 15.50
- S104G (p.Ser104Gly), NCI-TCGA TCGA novel, SIFT 0.42, Variant assessed as somatic; moderate impact.
- M106R (p.Met106Arg), Ensembl rs1577981210, SIFT 1.00
- H107P (p.His107Pro), Ensembl rs1577981209, SIFT 0.04
- F108S (p.Phe108Ser), Ensembl rs1577981207, REVEL 0.15, CADD 19.00
- P109R (p.Pro109Arg), gnomAD rs1295652148, REVEL 0.09, CADD 23.00
- H111Q (p.His111Gln), ExAC rs747260036, gnomAD rs747260036, REVEL 0.05, CADD 16.20
- M112I (p.Met112Ile), NCI-TCGA Cosmic COSV1005, REVEL 0.09, CADD 22.80, Variant assessed as somatic; moderate impact.
- T113A (p.Thr113Ala), Ensembl rs1699594245, REVEL 0.10, CADD 21.20
- T113N (p.Thr113Asn), gnomAD rs1699594197, REVEL 0.03, CADD 18.80
- I114V (p.Ile114Val), gnomAD rs1157043280, REVEL 0.14, CADD 22.00
- E115K (p.Glu115Lys), 1000Genomes rs184563116, ExAC rs184563116, TOPMed rs184563116, gnomAD rs184563116, REVEL 0.17, CADD 22.90
- E115Q (p.Glu115Gln), 1000Genomes rs184563116, ExAC rs184563116, TOPMed rs184563116, gnomAD rs184563116, REVEL 0.09, CADD 19.00
- P116S (p.Pro116Ser), TOPMed rs1026141784, REVEL 0.03, CADD 19.10
- S117N (p.Ser117Asn), gnomAD rs1431366387, REVEL 0.04, CADD 0.09
- T118I (p.Thr118Ile), NCI-TCGA Cosmic COSV5972, SIFT 0.00, Variant assessed as somatic; moderate impact.
- L120S (p.Leu120Ser), gnomAD rs1699593912, REVEL 0.18, CADD 19.70
- A121S (p.Ala121Ser), 1000Genomes rs149110022, ExAC rs149110022, TOPMed rs149110022, gnomAD rs149110022, REVEL 0.02, CADD 12.80
- A121T (p.Ala121Thr), 1000Genomes rs149110022, ExAC rs149110022, TOPMed rs149110022, gnomAD rs149110022, REVEL 0.03, CADD 15.40
- V122A (p.Val122Ala), ESP rs148085174, ExAC rs148085174, TOPMed rs148085174, gnomAD rs148085174, REVEL 0.15, CADD 21.50
- P123S (p.Pro123Ser), ExAC rs56287816, TOPMed rs56287816, gnomAD rs56287816, REVEL 0.06, CADD 15.20
- T124A (p.Thr124Ala), ExAC rs201783734, gnomAD rs201783734, REVEL 0.12, CADD 14.70
- T124N (p.Thr124Asn), gnomAD rs974162456, REVEL 0.05, CADD 12.00
- T124S (p.Thr124Ser), ExAC rs201783734, gnomAD rs201783734, SIFT 0.40
- L125V (p.Leu125Val), NCI-TCGA Cosmic COSV1005, Variant assessed as somatic; moderate impact.
- E126G (p.Glu126Gly), gnomAD rs1350834332, REVEL 0.17, CADD 24.70
- N129K (p.Asn129Lys), TOPMed rs1262811850, REVEL 0.11, CADD 23.50
- N133S (p.Asn133Ser), TOPMed rs1699593447, SIFT 0.00
- I135V (p.Ile135Val), ExAC rs761364189, gnomAD rs761364189, REVEL 0.10, CADD 18.40
- M136L (p.Met136Leu), ESP rs200978876, ExAC rs200978876, TOPMed rs200978876, gnomAD rs200978876, REVEL 0.03, CADD 19.00, Uncertain significance
- M136T (p.Met136Thr), ExAC rs767987176, TOPMed rs767987176, gnomAD rs767987176, REVEL 0.13, CADD 0.63
- M136V (p.Met136Val), rs200978876, ClinGen CA74732695, ClinVar RCV004087936, ESP rs200978876, REVEL 0.04, CADD 17.90, Uncertain significance, not specified
- P139H (p.Pro139His), NCI-TCGA Cosmic COSV5972, SIFT 0.00, Variant assessed as somatic; moderate impact.
- P139S (p.Pro139Ser), rs1402656322, NCI-TCGA Cosmic COSV1005, gnomAD rs1402656322, REVEL 0.39, CADD 24.80, Variant assessed as somatic; moderate impact.
- A140V (p.Ala140Val), rs200627901, ClinGen CA2430826, ClinVar RCV004472461, ExAC rs200627901, REVEL 0.10, CADD 21.00, Uncertain significance, not specified
- P142A (p.Pro142Ala), TOPMed rs1379324294, gnomAD rs1379324294, REVEL 0.37, CADD 25.00, Uncertain significance
- P142S (p.Pro142Ser), rs1379324294, ClinGen CA353102226, ClinVar RCV004098192, TOPMed rs1379324294, REVEL 0.37, CADD 25.60, Uncertain significance, not specified
- S144P (p.Ser144Pro), Ensembl rs1577981122
- I146T (p.Ile146Thr), NCI-TCGA Cosmic COSV5972, REVEL 0.36, CADD 2.14, Variant assessed as somatic; moderate impact.
- S147C (p.Ser147Cys), ExAC rs747419130, gnomAD rs747419130, REVEL 0.12, CADD 13.20
- S147F (p.Ser147Phe), NCI-TCGA Cosmic COSV5972, Variant assessed as somatic; moderate impact.
- S147P (p.Ser147Pro), TOPMed rs1577981119
- L148M (p.Leu148Met), TOPMed rs1424057961, REVEL 0.35, CADD 23.60
- S149P (p.Ser149Pro), Ensembl rs1577981105, REVEL 0.20, CADD 8.45
- S149Y (p.Ser149Tyr), ESP rs376087748, ExAC rs376087748, TOPMed rs376087748, gnomAD rs376087748, REVEL 0.15, CADD 15.60
- L150P (p.Leu150Pro), ExAC rs779052425, REVEL 0.43, CADD 24.40
- L150V (p.Leu150Val), TOPMed rs919277696, REVEL 0.18, CADD 22.10
- S151G (p.Ser151Gly), TOPMed rs1699592556, SIFT 0.02
- H152R (p.His152Arg), TOPMed rs1342987320, gnomAD rs1342987320, REVEL 0.14, CADD 0.15
- T153P (p.Thr153Pro), Ensembl rs1577981096
- L156P (p.Leu156Pro), rs1224643512, TOPMed rs1224643512, gnomAD rs1224643512, REVEL 0.31, CADD 23.20, Variant assessed as somatic; moderate impact.
- D159E (p.Asp159Glu), TOPMed rs1699592234
- A161T (p.Ala161Thr), TOPMed rs1298778487, gnomAD rs1298778487, REVEL 0.02, CADD 0.00
- L163I (p.Leu163Ile), rs201201841, ClinGen CA2430813, ClinVar RCV004231597, ExAC rs201201841, REVEL 0.08, CADD 4.38, Uncertain significance, not specified
- A164D (p.Ala164Asp), ExAC rs763686449, gnomAD rs763686449, REVEL 0.21, CADD 5.78
- A164G (p.Ala164Gly), NCI-TCGA TCGA novel, SIFT 0.16, Variant assessed as somatic; moderate impact.
- A164T (p.Ala164Thr), ExAC rs200062660, gnomAD rs200062660, REVEL 0.05, CADD 0.00
- G165S (p.Gly165Ser), rs201740851, NCI-TCGA Cosmic COSV5972, ExAC rs201740851, TOPMed rs201740851, REVEL 0.16, CADD 17.80, Variant assessed as somatic; moderate impact.
- L166P (p.Leu166Pro), ExAC rs771634375, gnomAD rs771634375, REVEL 0.44, CADD 23.60
- H167N (p.His167Asn), NCI-TCGA Cosmic COSV5972, SIFT 0.41, Variant assessed as somatic; moderate impact.
- H167Q (p.His167Gln), gnomAD rs1421307312, REVEL 0.07, CADD 0.00
- A168S (p.Ala168Ser), TOPMed rs1172566806, gnomAD rs1172566806, REVEL 0.02, CADD 0.24
- A168T (p.Ala168Thr), TOPMed rs1172566806, gnomAD rs1172566806
- A168V (p.Ala168Val), 1000Genomes rs201098493, ExAC rs201098493, TOPMed rs201098493, gnomAD rs201098493, REVEL 0.08, CADD 13.00
- R170C (p.Arg170Cys), TOPMed rs1011356526, gnomAD rs1011356526, REVEL 0.22, CADD 23.90
- R170H (p.Arg170His), ExAC rs199767102, TOPMed rs199767102, gnomAD rs199767102, REVEL 0.13, CADD 21.90
- R170S (p.Arg170Ser), TOPMed rs1011356526, gnomAD rs1011356526, REVEL 0.21, CADD 16.40
- F173C (p.Phe173Cys), Ensembl rs1699591449, SIFT 0.01
- G176D (p.Gly176Asp), NCI-TCGA Cosmic COSV5972, REVEL 0.28, CADD 24.10, Variant assessed as somatic; moderate impact.
- G176S (p.Gly176Ser), Ensembl rs1479202525, REVEL 0.19, CADD 23.70
- N177H (p.Asn177His), TOPMed rs1192636526, gnomAD rs1192636526
- N177S (p.Asn177Ser), TOPMed rs1405309670, gnomAD rs1405309670, REVEL 0.38, CADD 24.70
- N177Y (p.Asn177Tyr), TOPMed rs1192636526, gnomAD rs1192636526, REVEL 0.47, CADD 25.90, Uncertain significance, not specified
- Y179N (p.Tyr179Asn), TOPMed rs1699591251, gnomAD rs1699591251, REVEL 0.30, CADD 26.00
- Y180H (p.Tyr180His), ExAC rs768844402, gnomAD rs768844402, REVEL 0.26, CADD 25.80
- K181M (p.Lys181Met), NCI-TCGA TCGA novel, SIFT 0.02, Variant assessed as somatic; moderate impact.
- K181N (p.Lys181Asn), rs1438595607, NCI-TCGA Cosmic COSV1005, TOPMed rs1438595607, gnomAD rs1438595607, REVEL 0.12, CADD 21.90, Variant assessed as somatic; moderate impact.
- N182K (p.Asn182Lys), ExAC rs749405730, gnomAD rs749405730, REVEL 0.20, CADD 23.40
- P183L (p.Pro183Leu), ExAC rs780099835, gnomAD rs780099835, REVEL 0.28, CADD 25.60, Likely pathogenic
- P183R (p.Pro183Arg), rs780099835, ClinGen CA353101062, ClinVar RCV001172304, ExAC rs780099835, MutPred 0.57, Likely pathogenic, Esophageal atresia/tracheoesophageal fistula
- P183T (p.Pro183Thr), TOPMed rs777760744, gnomAD rs777760744, REVEL 0.45, CADD 25.70
- R185S (p.Arg185Ser), ExAC rs756098803, TOPMed rs756098803, gnomAD rs756098803, REVEL 0.17, CADD 0.04, Uncertain significance, Meniere disease
- A187E (p.Ala187Glu), ExAC rs750300739, gnomAD rs750300739, REVEL 0.14, CADD 14.60
- V190G (p.Val190Gly), Ensembl rs1577981012
Public TLR9 analysis runs
- TLR9 analysis run — TLR9 (1,506 variants) — completed 2026-08-19